CN110384685A - A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification - Google Patents
A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification Download PDFInfo
- Publication number
- CN110384685A CN110384685A CN201910829984.7A CN201910829984A CN110384685A CN 110384685 A CN110384685 A CN 110384685A CN 201910829984 A CN201910829984 A CN 201910829984A CN 110384685 A CN110384685 A CN 110384685A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- mof
- organic frame
- metal organic
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of metal organic frame pharmaceutical carriers and preparation method thereof of nucleic acid modification, belong to biomedical material technology.The present invention is used for the encapsulation and controlled release of metal organic frame pharmaceutical carrier by nucleic acid conformation variation, solves the leakage problem of drug before administration, reduces damage of the drug to normal cell.Metal organic frame is since controllable size, programmable hole shape, big struck capacity and specific surface area can load drug, and its surface has modifiability.It thus can be in conjunction with nucleic acid sequence, due to the variability of nucleic acid sequence structure, by control pH, it can be achieved that effective encapsulation to drug in metal organic frame duct.Compared with other pharmaceutical carriers based on metal organic frame, carrier of the present invention is harmless to the body, can effective encapsulated drug, avoid the aggregation and metabolism of organic polymer in vivo, in terms of drug loading and controlled release with good application prospect.
Description
Technical field
The present invention relates to a kind of new bio medical use multifunctional materials, and specifically a kind of metal of nucleic acid modification has
Machine frame pharmaceutical carrier and preparation method thereof.
Background technique
Malignant tumour, which has become, leads to one of principal disease of human death, seriously threatens the health of the mankind.According to
The newest statistical result showed of the World Health Organization, it is contemplated that arrive the year two thousand twenty, global cancer morbidity will increase by 50%, to 2030
Year, global number of cancer deaths will continue growing 74%.In the drug therapy of cancer, effective use of anticancer drug is one
Critically important link, it can help patient to obtain longer life span.But the stability of anticancer drug is poor, dissolubility
It is low, be easily metabolized and remove, have side effect, make it be difficult to give full play to drug effect over the course for the treatment of.Currently, with nanotechnology
With the rapid development of biomedical interdisciplinary science, metal organic frame pharmaceutical carrier plays significantly in the therapeutic process of tumour
Effect.Especially nearly ten years, metal-organic framework materials attract numerous concerns as the potentiality of pharmaceutical carrier, this is because golden
Belong to the designability of organic framework material, modifiability and it is degradable in vivo due to weak coordinate bond the advantages that.In spite of more
Constantly be reported come more pharmaceutical carriers, but drug is effectively encapsulated and controlled release it is considerably less, utilize nucleic acid
Conformation change carry out package metals organic frame drug delivery system and be rarely reported.
Currently, the stimuli responsive Drug controlled release based on metal organic frame carrying medicament be broadly divided into it is single stimulation and
Thorniness swashs two kinds.Common stimulus are as follows: pH, magnetic field, ion, temperature, illumination, pressure, redox etc..All by outer
In the metal organic frame pharmaceutical carrier of boundary's stimulation triggering, pH response type metal organic frame is because of the acid tumour micro-loop locating for it
Border and coordinate bond are widely studied the sensibility of extraneous pH.There are before drug release, drug gives vent to existing technology certainly
Leakage problem, although having rotaxane, succinic polymer, the reports such as beta-cyclodextrin are used for effective encapsulation of drug, these are organic
Object can bring certain side effect.Recently, Chen seminar reports " ATP-Responsive an Aptamer-Based
Metal–Organic Framework Nanoparticles(NMOFs)for the Controlled Release of
Loads and Drugs ", the aptamer modified metal organic frame drug delivery system of Wen Zhongyong ATP is packaged drug, meets
When to ATP, valve is opened, drug release.The technology has more advantage, but intracellular ATP compared to the encapsulation of traditional organic compound
Content is to limit.The present invention is used for the encapsulation and controlled release of metal organic frame pharmaceutical carrier by nucleic acid conformation variation,
The leakage problem of drug before administration is solved, damage of the drug to normal cell is reduced.Metal organic frame is due to controllable ruler
Very little, programmable hole shape, big struck capacity and specific surface area can load drug, and its surface has and can modify
Property.It thus can be in conjunction with nucleic acid sequence, due to the variability of nucleic acid sequence structure, by control pH, it can be achieved that organic to metal
Effective encapsulation of frame duct Chinese medicine object and controlled release.
Summary of the invention
Aiming at the problems existing in the prior art, the present invention provides a kind of metal organic frame drug loads of nucleic acid modification
Body.The present invention has constructed the metal organic frame of amino functional and has carried out the load of anti-tumor drug adriamycin, passes through acyl
The connection of amine key modifies the nucleic acid sequence 1 of carboxyl modified on metal organic frame surface, by hybridizing/solution with nucleic acid sequence 2
From encapsulation and controlled release for adriamycin.In the case where pH is neutrallty condition, drug is sealed in the phase mutual cross of nucleic acid sequence 1 and 2
Lock is in the hole of metal organic frame, and in the case where pH is solutions of weak acidity, nucleic acid sequence 2 and 1 is dissociated, and drug release comes out.
The present invention also provides a kind of preparation methods of the metal organic frame pharmaceutical carrier of nucleic acid modification.
The invention adopts the following technical scheme:
A kind of metal organic frame pharmaceutical carrier of nucleic acid modification, the pharmaceutical carrier be the variation based on nucleic acid conformation come
Package metals organic frame drug delivery system, by adjust pH induce nucleic acid conformation variation, and then realize drug encapsulation with
Controlled release.
A kind of preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification, it the following steps are included:
(1) 1,3,5- tri- (4- carboxyl phenyl), amino terephthalic acid (TPA) and zinc nitrate hexahydrate are dissolved in N, N ' diformazan
It in base formamide, is reacted 36 hours under the conditions of 85 DEG C, naturally cools to room temperature, obtained colorless prismatic crystal, then use N,
N ' dimethylformamide is washed and is impregnated 24 hours, rear to impregnate in methylene chloride, and every the solvent of exchange in 3 hours,
Finally vacuum drying obtains MOF-1；
(2) MOF-1 is ground by nanoscale MOF-1 using mechanical milling method；
(3) it is immersed in DNA1 solution and is shaken overnight using nanoscale MOF-1 prepared by step (2), centrifuge washing is dry
The dry MOF-1-DNA1 for obtaining surface modification nucleic acid sequence DNA1；
(4) MOF-1-DNA1 obtained by step (3) is immersed in doxorubicin hydrochloride aqueous solution, overnight, centrifuge washing is dry
Obtain DOX@MOF-1-DNA1；
(5) by the resulting DOX@MOF-1-DNA1 of step (4) under the buffer conditions of pH=7.4, DNA2, concussion is added
Overnight, the DOX@MOF-1-DNA1-DNA2 of block drug is obtained；
(6) the resulting DOX@MOF-1-DNA1-DNA2 of step (5) being placed in the buffer of pH=5.5, DNA2 solves fine jade,
Drug release realizes the controlled release of drug.
1,3,5- tri- (4- carboxyl phenyl), amino terephthalic acid (TPA), zinc nitrate hexahydrate and N, N ' two in the step (1)
The ratio of methylformamide is 38.5mg:36.5mg:241mg:8mL.
The sequence of DNA1 in the step (3) are as follows: SEQ ID NO.1.
The concentration of aqueous solution of doxorubicin hydrochloride is 1mg/mL in the step (4).
The sequence of the DNA2 are as follows: SEQ ID NO.2.The buffer is PBS buffer solution.
The invention has the advantages that our diversity based on nucleic acid structure, building pH induction nucleic acid structure variation, Jin Ershi
The encapsulation and controlled release of existing drug.Compared with other pharmaceutical carriers based on metal organic frame, what we selected is interior
Source property configuration metal ions Zn2+Ion, it is harmless to the body；Nitrogen adsorption test shows that the MOF-1 has biggish aperture, can be effective
Load drug；It is encapsulated with other organic polymers, nucleic acid modified metal organic frame avoids organic polymer in vivo poly-
Collection and metabolism.Therefore nucleic acid modification MOF-1 in terms of drug loading and controlled release with good application prospect.
Detailed description of the invention
The transmission electron microscope picture of Fig. 1 MOF-1.
Fig. 2 DNA1 modifies the ultra-violet absorption spectrum before and after MOF-1.
Fig. 3 DOX is by the ultra-violet absorption spectrum (0: the UV absorption of DOX before loading of MOF-1 load front and back；1:DOX is by MOF-
UV absorption after 1 load；2:DOX loaded by MOF-1 after UV absorption；).
The nitrogen adsorption effect picture of Fig. 4 MOF-1-DNA1 (1) and DOX@MOF-1-DNA1 (2).
Fig. 5 is based on adsorption of nitrogen gas data, the aperture figure (right side) of MOF-1-DNA1 (left side) and DOX@MOF-1-DNA1.
Fig. 6 DOX@MOF-1-DNA1 fluorescence intensity that DOX discharges in pH=5.5 buffer changes over time figure.
Fig. 7 DOX@MOF-1 fluorescence intensity that DOX discharges in pH=7.4 buffer changes over time figure.
Specific embodiment
The present invention is described in further detail combined with specific embodiments below.
Embodiment 1
A kind of metal organic frame pharmaceutical carrier of nucleic acid modification, it is prepared using following methods:
(1) 38.5mg 1,3,5- tri- (4- carboxyl phenyl), 36.5mg amino terephthalic acid (TPA) and 241mg six are hydrated nitre
Sour zinc is dissolved in 8mL N, in N ' dimethylformamide, reacts 36 hours under the conditions of 85 DEG C, naturally cools to room temperature, obtain
Then colorless prismatic crystal MOF-1 uses N, N ' dimethylformamide is washed and impregnated 24 hours, rear to impregnate in methylene chloride,
And it every the solvent of exchange in 3 hours, is finally dried in vacuo.
(2) 100mg MOF-1 obtained is subjected to grinding half an hour by step (1), nanoscale MOF-1 is made, such as Fig. 1 institute
Show.
(3) it takes 10mg nanometers of MOF-1 obtained by step (2) to be immersed in 100 μM of DNA1 solution to shake overnight, centrifuge washing,
It is dried to obtain the MOF-1-DNA1 of surface modification nucleic acid sequence DNA1.The ultra-violet absorption spectrum of DNA1 modification front and back is surveyed
Examination, as a result as shown in Fig. 2, 10mg nanometers of MOF-1 can modify 50 μM of DNA1.
(4) MOF-1 and MOF-1-DNA1 are separately immersed in doxorubicin hydrochloride (1mg/mL) aqueous solution, overnight, centrifugation,
Washing, is dried to obtain DOX@MOF-1 and [email protected] ultra-violet absorption spectrum of DOX load front and back is tested.
As a result as shown in Fig. 3, MOF-1 and MOF-1-DNA1 are respectively 32 and 31.2mg/g to the load capacity of DOX.It should be the result shows that core
Acid modification MOF-1 does not influence the drugloading rate of MOF-1.In addition, the nitrogen that we test DOX load front and back pharmaceutical carrier is inhaled
Attached, as a result shown in attached Figure 4 and 5, before DOX load, there are three aperture 1.35nm, 1.09nm and 0.78nm, specific surface areas
2769m2·g-1, and after DOX load, aperture 1.35nm and 1.09nm disappear, and specific surface area drops to 535m2·g-1.This result
Illustrate that MOF-1 being capable of payload DOX.
(5) in the PBS solution of pH=7.4, DOX@MOF-1-DNA1 and DNA2 is added, concussion overnight, obtains block medicine
The DOX@MOF-1-DNA1-DNA2 of object.
(6) DOX@MOF-1-DNA1-DNA2 prepared by above-mentioned steps (5) is placed in the PBS solution of pH=5.5,
DNA2 solves fine jade, drug release, by the release conditions for testing fluorescence intensity Observable drug.As shown in Fig. 6, with the time
Increase, the fluorescence of DOX gradually increases, and illustrates drug release；The resulting DOX@MOF-1-DNA1-DNA2 of above-mentioned steps (5) is set
Control experiment is used as in the buffer solution of pH=7.4, the fluorescence intensity of DOX is weak at this time, and in 120min also not
It significantlys change increase with time.However it is discharged very in the buffer of pH=7.4 without the DOX@MOF-1 of nucleic acid modification
Fastly, at 1 hour with regard to substantially all release, as shown in Fig. 7.The necessity and core of result further explanation drug pack
Acid modification MOF-1 realizes the effective encapsulation and controlled release of drug DOX.
Sequence table
<110>Linyi University
<120>a kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification
<160> 2
<170> SIPOSequenceListing 1.0
<210> 3
<211> 12
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
gagtacggag gg 12
<210> 2
<211> 60
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
ggaggggagg ggaggttatc ctcccctccc ctccctttgc ctcccctccc ctccgtactc 60
Claims (7)
1. a kind of metal organic frame pharmaceutical carrier of nucleic acid modification, which is characterized in that the pharmaceutical carrier is based on nucleic acid knot
The variation of structure carrys out package metals organic frame drug delivery system, induces nucleic acid structure variation by adjusting pH, and then realize medicine
The encapsulation and controlled release of object.
2. a kind of preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification described in claim 1, which is characterized in that
It the following steps are included:
(1) 1,3,5- tri- (4- carboxyl phenyl), amino terephthalic acid (TPA) and zinc nitrate hexahydrate are dissolved in N, N ' dimethyl methyl
It in amide, is reacted 36 hours under the conditions of 85 DEG C, naturally cools to room temperature, obtained colorless prismatic crystal, then use N, N ' two
Methylformamide is washed and is impregnated 24 hours, rear to impregnate in methylene chloride, and every the solvent of exchange in 3 hours, finally
Vacuum drying obtains MOF-1；
(2) MOF-1 is ground by nanoscale MOF-1 using mechanical milling method；
(3) it is immersed in DNA1 solution and is shaken overnight using nanoscale MOF-1 prepared by step (2), centrifuge washing is dry
To the MOF-1-DNA1 of surface modification nucleic acid sequence DNA1；
(4) MOF-1-DNA1 obtained by step (3) is immersed in doxorubicin hydrochloride aqueous solution, overnight, centrifuge washing is dried to obtain
DOX@MOF-1-DNA1；
(5) by the resulting DOX@MOF-1-DNA1 of step (4) under the buffer conditions of pH=7.4, DNA2 is added, shook
Night obtains the DOX@MOF-1-DNA1-DNA2 of block drug；
(6) the resulting DOX@MOF-1-DNA1-DNA2 of step (5) is placed in the buffer of pH=5.5, DNA2 solves fine jade, drug
Release, realizes the controlled release of drug.
3. the preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification according to claim 2, which is characterized in that
1,3,5- tri- (4- carboxyl phenyl), amino terephthalic acid (TPA), zinc nitrate hexahydrate and N, N ' dimethyl formyl in the step (1)
The ratio of amine is 38.5mg:36.5mg:241mg:8mL.
4. the preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification according to claim 2, which is characterized in that
The sequence of DNA1 in the step (3) are as follows: SEQ ID NO.1.
5. the preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification according to claim 2, which is characterized in that
The concentration of aqueous solution of doxorubicin hydrochloride is 1mg/mL in the step (4).
6. the preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification according to claim 2, which is characterized in that
The sequence of the DNA2 are as follows: SEQ ID NO.2.
7. the preparation method of the metal organic frame pharmaceutical carrier of nucleic acid modification according to claim 2, which is characterized in that
The buffer is PBS buffer solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910829984.7A CN110384685A (en) | 2019-09-04 | 2019-09-04 | A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910829984.7A CN110384685A (en) | 2019-09-04 | 2019-09-04 | A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110384685A true CN110384685A (en) | 2019-10-29 |
Family
ID=68289715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910829984.7A Pending CN110384685A (en) | 2019-09-04 | 2019-09-04 | A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110384685A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105021585A (en) * | 2015-08-04 | 2015-11-04 | 深圳职业技术学院 | Method for detecting food-borne pathogenic bacteria on basis of metal organic framework material and aptamer fluorescence sensor |
| CN105056915A (en) * | 2015-08-07 | 2015-11-18 | 兴义民族师范学院 | Preparation and application for magnetic metal organic framework medium modified by nucleic acid aptamer |
| CN106975373A (en) * | 2017-04-14 | 2017-07-25 | 浙江大学 | Metal organic framework thin film of DNA modification and its preparation method and application |
| CN109111575A (en) * | 2018-05-23 | 2019-01-01 | 中山大学 | A kind of preparation method and application of metal-organic framework nano particle |
| CN110136998A (en) * | 2019-06-19 | 2019-08-16 | 临沂大学 | A kind of preparation method and applications of metal organic framework carbon fiber laminated film |
-
2019
- 2019-09-04 CN CN201910829984.7A patent/CN110384685A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105021585A (en) * | 2015-08-04 | 2015-11-04 | 深圳职业技术学院 | Method for detecting food-borne pathogenic bacteria on basis of metal organic framework material and aptamer fluorescence sensor |
| CN105056915A (en) * | 2015-08-07 | 2015-11-18 | 兴义民族师范学院 | Preparation and application for magnetic metal organic framework medium modified by nucleic acid aptamer |
| CN106975373A (en) * | 2017-04-14 | 2017-07-25 | 浙江大学 | Metal organic framework thin film of DNA modification and its preparation method and application |
| CN109111575A (en) * | 2018-05-23 | 2019-01-01 | 中山大学 | A kind of preparation method and application of metal-organic framework nano particle |
| CN110136998A (en) * | 2019-06-19 | 2019-08-16 | 临沂大学 | A kind of preparation method and applications of metal organic framework carbon fiber laminated film |
Non-Patent Citations (3)
| Title |
|---|
| JASON S. KAHN等: ""Stimuli-Responsive DNA-Functionalized Metal–Organic Frameworks (MOFs)"", 《ADVANCED SCIENCE NEWS》 * |
| YUANCHAO ZHANG等: ""DNA-Functionalized Metal−Organic Framework: Cell Imaging, Targeting Drug Delivery and Photodynamic Therapy"", 《INORG. CHEM.》 * |
| 张远超: ""金属有机框架用于肿瘤诊断、治疗的研究"", 《中国优秀硕士论文全文数据库 工程科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Della Rocca et al. | Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy | |
| Secret et al. | Anionic porphyrin-grafted porous silicon nanoparticles for photodynamic therapy | |
| Zakaria et al. | Prussian blue derived nanoporous iron oxides as anticancer drug carriers for magnetic‐guided chemotherapy | |
| Zhou et al. | Oxygenated theranostic nanoplatforms with intracellular agglomeration behavior for improving the treatment efficacy of hypoxic tumors | |
| CN108178803B (en) | Preparation of drug-loaded cinnamaldehyde-glucan polymer self-assembled nanoparticles and anti-tumor application thereof | |
| Qiu et al. | Triple-stimuli (protease/redox/pH) sensitive porous silica nanocarriers for drug delivery | |
| Resen et al. | Effectiveness of 5-Fluorouracil and gemcitabine hydrochloride loaded iron‑based chitosan-coated MIL-100 composite as an advanced, biocompatible, pH-sensitive and smart drug delivery system on breast cancer therapy | |
| Shao et al. | Facile Synthesis of Core–shell Magnetic Mesoporous Silica Nanoparticles for pH‐sensitive Anticancer Drug Delivery | |
| CN105315455A (en) | Preparation of glutamic acid modified polyethylene glycol monostearate and application of glutamic acid modified polyethylene glycol monostearate in target drug transfer | |
| JP2008527134A (en) | Dosage form in which hydrophobic anticancer agent is encapsulated inside bile acid-chitosan complex and method for producing the same | |
| Chen et al. | New strategy for precise cancer therapy: tumor-specific delivery of mitochondria-targeting photodynamic therapy agents and in situ O 2-generation in hypoxic tumors | |
| CN104998261B (en) | Double drug-loading fluorescent magnetic microsphere composite system and preparation method thereof | |
| CN104587485A (en) | Preparation method of tirapazamine-gold nanoparticle compound and application of tirapazamine-gold nanoparticle compound | |
| Li et al. | A fluorescence and photoactivity dual-activatable prodrug with self-synergistic magnification of the anticancer effect | |
| Zhang et al. | Co-delivery of rose bengal and doxorubicin nanoparticles for combination photodynamic and chemo-therapy | |
| Cai et al. | Recent advances in functional carbon quantum dots for antitumour | |
| CN106474090B (en) | A kind of load ruthenium complex nanometer particle and its preparation and application | |
| Kansara et al. | Graphene quantum dots: A review on the effect of synthesis parameters and theranostic applications | |
| CN102698282A (en) | Preparation method for multi-responsive magnetic composite nanoparticles for loading medicament | |
| Wang et al. | Multifunctional nano-realgar hydrogel for enhanced glioblastoma synergistic chemotherapy and radiotherapy: a new paradigm of an old drug | |
| Meng et al. | Gold nanoclusters exert antibacterial effects against gram-negative bacteria by targeting thiol-redox homeostasis | |
| CN104940951B (en) | A kind of preparation method of magnetizing reduction response antineoplastic drug carrier | |
| CN110384685A (en) | A kind of metal organic frame pharmaceutical carrier and preparation method thereof of nucleic acid modification | |
| CN109233820A (en) | A kind of g-C3N4Quantum dot and its preparation method and application | |
| CN105853373A (en) | Zinc oxide-based nano-drug composition, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191029 |